.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,022,095

« Back to Dashboard

Claims for Patent: 8,022,095

Title:Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
Abstract: The invention is directed to methods and compositions that can be used in the treatment of headaches. In particular, methods and compositions are described involving the combination of a long-acting NSAID and a 5-HT1.sub.B/1.sub.D agonist.
Inventor(s): Plachetka; John R. (Chapel Hill, NC)
Assignee: Pozen, Inc. (Chapel Hill, NC)
Application Number:10/414,493
Patent Claims: 1. A pharmaceutical composition useful in treating migraine headache which comprises in a unit dosage form: (a) naproxen; and (b) sumatriptan; wherein the respective amounts of sumatriptan and naproxen in said pharmaceutical composition are effective upon simultaneous administration of one or more unit dosage forms, to produce longer lasting efficacy compared to the administration of sumatriptan in the absence of naproxen or the administration of naproxen in the absence of sumatriptan; and wherein the sumatriptan is present at about 85 mg and the naproxen is present at about 500 mg.

2. A pharmaceutical composition useful in treating migraine headache which comprises in a unit dosage form: (a) naproxen sodium; and (b) sumatriptan; wherein the respective amounts of sumatriptan and naproxen in said pharmaceutical composition are effective upon simultaneous administration of one or more unit dosage forms, to produce longer lasting efficacy compared to the administration of sumatriptan in the absence of naproxen or the administration of naproxen in the absence of sumatriptan; and wherein sumatriptan is present at about 85 mg and naproxen sodium is present at about 500 mg.

3. A pharmaceutical composition useful in treating migraine headache which comprises in a unit dosage form: (a) naproxen sodium; and (b) sumatriptan; wherein the respective amounts of sumatriptan and naproxen in said pharmaceutical composition are effective upon simultaneous administration of one or more unit dosage forms, to produce longer lasting efficacy compared to the administration of sumatriptan in the absence of naproxen or the administration of naproxen in the absence of sumatriptan; and wherein sumatriptan is present at about 50 mg and naproxen sodium is present at about 500 mg.

4. A method of treating a patient for a migraine headache, comprising simultaneously administering to said patient: (a) sumatriptan; and (b) naproxen; wherein: sumatriptan and naproxen are administered to said patient orally after the onset of migraine symptoms; and the amount of sumatriptan and naproxen administered to said patient are sufficient to produce longer lasting efficacy compared to the administration of sumatriptan in the absence of naproxen or the administration of naproxen in the absence of sumatriptan; and wherein sumatriptan is administered at an amount of about 50 mg and naproxen is administered at an amount of about 500 mg.

5. A method of treating a patient for a migraine headache, comprising simultaneously administering to said patient: (a) sumatriptan; and (b) naproxen; wherein: sumatriptan and naproxen are administered to said patient orally after the onset of migraine symptoms; and the amount of sumatriptan and naproxen administered to said patient are sufficient to produce longer lasting efficacy compared to the administration of sumatriptan in the absence of naproxen or the administration of naproxen in the absence of sumatriptan; and wherein sumatriptan is administered at an amount of about 100 mg and naproxen is administered at an amount of about 500 mg.

6. A method of treating a patient for a migraine headache, comprising simultaneously administering to said patient: (a) sumatriptan; and (b) naproxen sodium; wherein: sumatriptan and naproxen sodium are administered to said patient orally after the onset of migraine symptoms; and the amount of sumatriptan and naproxen sodium administered to said patient are sufficient to produce longer lasting efficacy compared to the administration of sumatriptan in the absence of naproxen sodium or the administration of naproxen sodium in the absence of sumatriptan; and wherein sumatriptan is administered at an amount of about 85 mg and naproxen sodium is administered at an amount of about 500 mg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc